The Munich-based firm has landed a big pharma partner in Bristol Myers Squibb, claiming the deal validates the potential of its approach in developing next-generation antibody-drug conjugates.
Tubulis GmbH is the latest biotech to benefit from big pharma's surge of interest in next-generation antibody-drug conjugates (ADCs), inking a deal that could be worth over $1bn.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.
The San Diego biotech’s lead product candidate is an antisense oligonucleotide-based therapy slated to enter Phase III development in the third quarter.
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.
The companies will co-develop the drug for additional indications beyond Huntington’s disease, while Prilenia retains rights in key global markets.
